HEALTHMay 25 · 13:39 UTCSCIENCE DAILY

Scientists discover why Ozempic and Wegovy weight loss eventually plateaus

New NIH research reveals that semaglutide triggers varied responses in appetite-controlling brain cells, explaining why GLP-1 weight-loss drugs like Ozempic and Wegovy lose effectiveness over time. Scientists also identified a potential method to prolong the drugs' efficacy, helping patients overcome weight-loss plateaus.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

National Institutes of HealthorganizationOzempicproductWegovyproductsemaglutidedrugGLP-1topicappetite-controlling brain cellstopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHApr 16 · 11:00 UTC
This could be why your weight-loss medication isn’t delivering results
HEALTHMay 4 · 06:14 UTC
Weight loss drug Ozempic linked to lower depression and anxiety risk
SCIENCEMay 6 · 00:00 UTC
A brain reward circuit inhibited by next-generation weight-loss drugs in mice
HEALTHApr 17 · 03:49 UTC
Scientists discover natural hormone that reverses obesity
HEALTHApr 14 · 11:00 UTC
Popular weight-loss medications linked to hidden side effects, study finds
HEALTHMay 7 · 10:37 UTC
New “Trojan horse” obesity drug supercharges weight loss in early tests